Renovorx Inc (RNXT) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Renovorx Inc   (NASDAQ: RNXT)
 

Renovorx Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Renovorx Inc inventory turnover ratio, the Renovorx Inc 's ability to sell and replace its inventory in the third quarter 2026, sequentially increased to 1.37 in the third quarter 2026, RNXT's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Renovorx Inc in Sep 30 2026 quarter, has decreased to 266 days, compare to 361 days, in the Jun 30 2026 quarter.

Within Healthcare sector 311 other companies have achieved higher inventory turnover ratio. While inventory turnover ranking remained unchanged in the Third Quarter 2026 compared to previous quarter at no. .

RNXT Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Renovorx Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RNXT Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth 25.37 % - - - -
Y / Y Cost of Sales Growth 254.72 % -5.92 % -10.64 % - -
Inventory Turnover Ratio (TTM) 1.37 1.01 1.51 2.84 4.4
RNXT's Total Ranking # # # # #
Average inventory processing period 266 362 242 129 83
Seq. Inventory Growth -10.97 % 1.06 % 100.53 % -30.51 % -
Seq. Cost of Sales Growth 31.47 % 70.24 % 200 % -47.17 % -65.13 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 92
Healthcare Sector # 312
Overall Market #

Inventory Turnover Ratio Statistics
High Average Low
1.01 1.01 1.01
(Jun 30 2026)  



RNXT Company Profile >> Back to RNXT Efficiency Comparisons >> Compare RNXT Inventory Turnover Ratio to its Competitors

Financial Statements
Renovorx Inc 's Inventories $ 0 Millions Visit RNXT's Balance sheet
Renovorx Inc 's Cost of Revenues TTM $ 0 Millions Visit RNXT's Income Statement
What are RNXT's Sales? Visit RNXT's Sales by Segment

Other Inventory Turnover Ratios
Renovorx Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
RNXT's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for RNXT's Competitors
Inventory Turnover Ratio for RNXT's Suppliers
Inventory Turnover Ratio for RNXT's Customers

You may also want to know
RNXT's Sales Growth Rates RNXT's Pe Price to earnings ratio RNXT's Receivables Turnover Ratio RNXT's Stock Quote
RNXT's Net Income Growth Rates RNXT's Ps Price to Sales ratio RNXT's Sales per Employee RNXT's Asset Turnover Ratio
RNXT's Net Margin RNXT's Pb Price to Book ratio RNXT's Financial Strength Ratios RNXT's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Baxter International Inc   3.57 $ 8,117.000  Millions$ 2,277  Millions
Bausch Health Companies Inc   3.54 $ 4,518.000  Millions$ 1,276  Millions
Exelixis Inc   3.49 $ 93.324  Millions$ 27  Millions
Abbvie Inc   3.40 $ 17,346.000  Millions$ 5,108  Millions
Gilead Sciences Inc   3.30 $ 6,219.000  Millions$ 1,884  Millions
Iovance Biotherapeutics inc   3.21 $ 177.232  Millions$ 55  Millions
Teva Pharmaceutical Industries Limited  3.16 $ 8,011.000  Millions$ 2,537  Millions
Msa Safety Inc  3.00 $ 1,063.235  Millions$ 354  Millions
Mimedx Group Inc   2.98 $ 70.562  Millions$ 24  Millions
Ligand Pharmaceuticals Incorporated  2.93 $ 34.495  Millions$ 12  Millions
Neogen Corporation  2.89 $ 464.774  Millions$ 161  Millions
Ani Pharmaceuticals Inc  2.87 $ 405.540  Millions$ 142  Millions
Zevra Therapeutics Inc   2.82 $ 6.736  Millions$ 2  Millions
Biomerica Inc   2.65 $ 4.297  Millions$ 2  Millions
Dexcom Inc   2.65 $ 1,867.500  Millions$ 705  Millions
Dentsply Sirona Inc   2.65 $ 1,769.000  Millions$ 668  Millions
Avita Medical Inc   2.58 $ 14.936  Millions$ 6  Millions
Angiodynamics Inc   2.50 $ 142.709  Millions$ 57  Millions
Pro dex Inc   2.45 $ 53.753  Millions$ 22  Millions
Illumina Inc   2.36 $ 1,458.000  Millions$ 618  Millions
Mirum Pharmaceuticals Inc   2.35 $ 59.684  Millions$ 25  Millions
Aquestive Therapeutics Inc   2.34 $ 16.928  Millions$ 7  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Rigel Pharmaceuticals Inc  2.24 $ 29.869  Millions$ 13  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions
Johnson and Johnson  2.17 $ 32,222.000  Millions$ 14,824  Millions
Standard Biotools Inc   2.16 $ 39.539  Millions$ 18  Millions
Icu Medical Inc  2.14 $ 1,304.538  Millions$ 609  Millions

Date modified: 2026-11-06T13:00:20+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.